| abstract |
The disclosure provides methods of preventing or treating heart failure in a mammalian subject, reducing risk factors associated with heart failure, and / or reducing the likelihood or severity of heart failure. The disclosure also provides methods of preventing, or treating LV remodeling in a mammalian subject, and / or reducing the likelihood or severity of LV remodeling. The methods comprise administering to a subject an effective amount of a cationic aromatic peptide. In some embodiments, the methods comprise administering to a subject an effective amount of a cationic aromatic peptide to reduce levels of C-reactive protein, tumor necrosis factor alpha, interleukin-6, reactive oxygen species, Nt-pro BNP, and / or cardiac troponin I, and / or reduce the expression levels of MLCL AT1 and / or ALCAT1 in subjects in need thereof. In some embodiments, the methods comprise administering to a subject an effective amount of a cationic aromatic peptide to increase Taz1 expression and / or increase mk ATP activity in subjects in need thereof. |